Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Anti-migraine Drugs Market $25.1 Billion by 2031

The global market for acute and preventive anti-migraine drugs estimated reach $25.1 billion by 2031, expanding at a double-digit CAGR of 10.2% over the forecast period, driven by enormous patient population, high cost of innovative new drugs, and strong pipeline of novel therapies.

  • The launch and continued strong uptake of biologic calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventative treatment of migraine has transformed the sales outlook for migraine disease.
    • New developments in this field have the potential to improve the diagnosis and provide more individualized treatments for this condition. It appears that the COVID-19 pandemic largely has not had a big impact on sales of novel migraine therapies. In fact, the overall sales of new migraine drugs for preventive therapies or acute treatments increased in the recent years.
  • However, additional flexibility in route of administration for this mechanism has created new pipeline treatments and opens a new commercial avenue for use in both prevention and acute migraine attacks for existing and novel migraine treatments.
Global Anti-migraine Drugs Market

Migraine treatment is divided into two paradigms: acute treatment, which is taken as an abortive treatment at the onset of an attack, and prophylactic treatment, which is administered chronically to prevent new migraine attacks.

Migraine treatment traditionally includes both preventive therapies, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks.

  • For decades, migraine-inhibiting drugs were limited to conventional and non-specific analgesics and non-steroidal anti-inflammatory drugs. Acute anti-migraine medications are exclusively over-the-counter, including prescription analgesics. Therefore, the market for prescription acute and preventive migraine treatments has been stable and largely generic for many years. However, recent years have seen the emergence of novel acute and preventive migraine treatments that target different neural mechanisms and/or act via innovative delivery systems.
    • The triptans, a class of selective and highly effective 5-HT1B/1D receptor agonists (Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, and Zolmitriptan) are the main prescription drugs.
    • The most commonly prescribed migraine prevention or prophylactic drugs are antiepileptic drugs (topiramate), beta blockers (propranolol, atenelol, metoprolol and bisoprolol) and tricyclic antidepressants (amitriptyline).
    • The first two FDA-approved CGRP-targeted monoclonal antibody (Anti-CGRP mAbs) preventive therapies were fremanezumab (Ajovy) and erenumab (Aimovig). Later, Eli Lilly’s galcanezumab (Emgality), and Lundbeck’s eptinezumab (Vyepti) were approved by the US FDA to become the other available CGRP blockers on the market.
    • The new drug class for acute migraine has been proven to reduce the chance and severity of migraine attacks. These drugs work by blocking the action of a protein fragment called calcitonin gene-related peptide (CGRP). CGRP-blocking drugs are a revolutionary development in migraine treatment and prevention.
      • The oral CGRP-targeted therapies as CGRP receptor antagonists include AbbVie’s atogepant (Qulipta) and ubrogepant (Ubrelvy), Biohaven/Prizer’s’s rimegepant (Nurtec ODT/Vydura), and zavegepant (Zavzpret).
    • Other emerging pharmacological strategies for acute and preventive migraine treatment that are nearing or have already entered the clinical trial phase.

The global market for migraine-inhibiting drugs research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global antimigraine drugs market segmented by product (drug class/brand) – acute agents [Triptans, Oral anti-CGRPs [Ubrelvy (ubrogepant), Nurtec ODT/Vydura (rimegepant), Qulipta (atogepant), Zavzpret (zavegepant), other agents [Reyvow (lasmiditan)], others], preventive agents [Botox (onabotulinum toxin A), anti-CGRP mAbs [Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), Vyepti (eptinezumab)], oral anti-CGRPs, others], and geography.

  • Presently, the migraine market is dominated by the generic triptan class, however, recently approved novel monoclonal antibody therapies specifically against a CGRP or its receptor target to prevent these types of headaches are going to change that scenario over the forecast period.
    • The launch of the CGRP inhibitors marked the biggest shakeup in the migraine market.
    • The acute migraine market is mainly driven by the oral CGRP antagonists, which could double in size over the forecast period.
      • The launch of new prophylactic drugs (CGRP-targeted monoclonal antibody, Anti-CGRP mAbs) with enhanced efficacy and tolerability data, the global market is primed for dramatic growth over the next 10 years.
        • Initial indicators point to rapid, early adoption of anti-CGRP mAbs in the US, likely due to high demand for improved options, higher cost of these therapies (approx. $6,900 per year in the US), and enormous population size.
      • There is clearly a large unmet need for preventative therapy. Both migraine treatment penetration and anti-CGRP class share are likely grown significantly over the coming years.
        • The acute migraine market is mainly driven by the oral CGRP antagonists, which could double in size over the forecast period. The launch of the CGRP inhibitors marked the biggest shakeup in the migraine market.

The global market for anti-migraine drugs research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Migraine is a highly prevalent disease and disabling neurological disorder. The American Migraine Foundation estimates migraine headaches affect 38 million in US alone, with three times greater prevalence in females. Its prevalence is highest in the Americas, followed by Europe, whereas it is lower in Africa and Asia.

In addition, the global market for anti-migraine treatment report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for anti-migraine drugs and profiled in this report include AbbVie, Inc., Amgen, Inc., Biohaven Pharmaceuticals, Inc., Eli Lilly and Company, GSK plc (GlaxoSmithKline), H. Lundbeck A/S, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

  • Product (Drug Class/Brand)
    • Acute Agents
      • Triptans
      • Oral Anti-CGRPs [Calcitonin Gene-Related Peptide (CGRP) Antagonist]
        • Ubrelvy (ubrogepant)
        • Nurtec/Vydura (rimegepant)
        • Qulipta (atogepant)
        • Zavzpret (zavegepant) nasal spray
      • Other Acute Agents (Neurally Acting Antimigraine Agent)
        • Reyvow (lasmiditan)
      • Others
    • Preventive / Prophylactic Agents
      • Botox (Onabotulinum toxin A)
      • Anti-CGRP mAbs
        • Aimovig (erenumab)
        • Emgality (galcanezumab)
        • Ajovy (fremanezumab)
        • Vyepti (eptinezumab)
      • Oral Anti-CGRPs
      • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc.
    • Amgen, Inc.
    • Biohaven Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • GSK plc (GlaxoSmithKline)
    • H. Lundbeck A/S
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com